Disintegrin and metalloproteinase domain-containing protein 17 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Disintegrin and metalloproteinase domain-containing protein 17 shows clinical signal disease relevance led by rheumatoid arthritis. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P78536. Start with rheumatoid arthritis, then reuse UniProt P78536 as the stable protein anchor across project notes and exports.
Start with rheumatoid arthritis, then reuse UniProt P78536 as the stable protein anchor across project notes and exports.
Disintegrin and metalloproteinase domain-containing protein 17 shows clinical signal disease relevance led by rheumatoid arthritis. 1 linked drug remains visible in the same block.
Start review with rheumatoid arthritis because it currently carries clinical signal support. Linked drugs include APRATASTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyDisintegrin and metalloproteinase domain-containing protein 17
Review this target as Disintegrin and metalloproteinase domain-containing protein 17, mapped to UniProt P78536. Sequence length is 824 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Disintegrin and metalloproteinase domain-containing protein 17 as ChEMBL target CHEMBL3706, mapped to UniProt P78536. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Disintegrin and metalloproteinase domain-containing protein 17 is the right protein anchor across sources, using UniProt P78536 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why rheumatoid arthritis is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Disintegrin and metalloproteinase domain-containing protein 17 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P78536 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Disintegrin and metalloproteinase domain-containing protein 17 |
| UniProt Accession | P78536 |
| Component Type | Protein |
| Sequence Length | 824 aa |
Disintegrin and metalloproteinase domain-containing protein 17
Review this target as Disintegrin and metalloproteinase domain-containing protein 17, mapped to UniProt P78536. Sequence length is 824 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Disintegrin and metalloproteinase domain-containing protein 17 shows clinical signal disease relevance led by rheumatoid arthritis.
Start review with rheumatoid arthritis because it currently carries clinical signal support. Linked drugs include APRATASTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL391851 | 10.59 | IC50 | 0.026 | Preclinical |
| CHEMBL1288122 | 10.22 | Ki | 0.06 | Preclinical |
| CHEMBL148169 | 10.22 | Ki | 0.06 | Preclinical |
| CHEMBL1288000 | 10.15 | Ki | 0.07 | Preclinical |
| CHEMBL1630098 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL4082554 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL1288726 | 10.0 | Ki | 0.1 | Preclinical |
| CHEMBL1222942 | 10.0 | Ki | 0.1 | Preclinical |
| CHEMBL1288059 | 9.89 | Ki | 0.13 | Preclinical |
| CHEMBL271235 | 9.85 | IC50 | 0.14 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 200 | 1,542 | 7.3 |
| cell-based format | 52 | 138 | 6.5 |
| tissue-based format | 3 | 100 | 8.1 |
| assay format | 2 | 28 | 7.6 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| tissue-based format | 13 | 229 | 6.4 |
| assay format | 9 | 95 | 5.8 |
| cell-based format | 3 | 15 | 6.0 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 3 | 3 | 5.5 |
| single protein format | 2 | 1 | 6.3 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 3 | 7.3 |